November 20, 2024 8:03am

After a lost 2024 of cell and gene therapy sector valuation and share pricing

News: Sangamo Therapeutics (SGMO +$0.25) U.S. FDA has cleared the investigational new drug (IND) application for its ST-503 program, an investigational epigenetic regulator for the treatment of intractable pain due to idiopathic small fiber neuropathy (iSFN), a type of chronic neuropathic pain. Sage Therapeutics (SAGE -$0.11) today announced topline results from the P2 DIMENSION Study of dalzanemdor (SAGE-718) in participants with cognitive impairment (CI) associated with Huntington’s Disease (HD). In the study, dalzanemdor did not demonstrate a statistically significant difference versus placebo on the primary endpoint, SAGE does not plan further development of dalzanemdor.

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!

MY Pre-Open Thoughts: 9 Positive and 3 Negative Indications

Never leave an investor uninform

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!

 

RegMed Investors (RMi) Closing Bell: green on the screen; yet, there is still red in the portfolio … https://www.regmedinvestors.com/articles/13704

RegMed Investors (RMi) - Q3/24 Cell and Gene Therapy Earnings Scorecard Results … https://www.regmedinvestors.com/articles/11628

 

Wednesday: The pre-open Dow futures are UP +0.29% (+124 points), the S&P futures are UP +0.18% or (+10 points) and the Nasdaq futures are UP +0.22% or (+45 points)

  • Futures ticked higher on Wednesday, 11/20,
  • European markets traded higher,
  • Asia-Pacific markets were mostly lower.

 

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

Tuesday: The Dow closed DOWN -120.66 points or -0.28%, the S&P closed UP +23.36 points or +0.40% while the Nasdaq closed UP +195.66 points or +1.04%

  • Tuesday’s advance/decline line ended with a positive close at the close of 19 incliner, 14 decliners and 2 flats

Economic Data Docket: MBA mortgage applications, Nov. 15 (0.5% prior)

 

Q4/24: November 8 negative and 5 positive closes

  • October: 8 positive and 15 negative closes

Q3/24:

  • September – 10 positive and 10 negative close
  • August – I neutral, 10 positive and 11 negative closes
  • July: 1 market holiday. 1 day off, 6 negative, 1 neutral and 12 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context 

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.

A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Positive Indications:

Tuesday, Monday, Friday, Thursday, Wednesday and last Tuesday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)      

Beam Therapeutics (BEAM) closed up +$1.17 after Monday’s +$0.07, Friday’s -$2.26, Thursday’s -$0.31, Wednesday’s -$0.44 and last Tuesday’s -$2.41 following the previous Monday’s +$3.29 with a positive +$0.19 or +0.75% aftermarket

Sangamo Therapeutics (SGMO) closed up +$0.06 with a positive +$0.26 or +13.25% aftermarket on news <above in title>

Ultragenyx Pharmaceuticals (RARE) closed UP +$1.35 after Monday’s -$0.97, Friday’s -$2.89, Thursday’s -$1.07 and last Wednesday’s +$0.87 following the previous Tuesday’s -$2.89 with a positive +0.87 or +1.93% aftermarket   

CRISPR Therapeutics (CRSP) closed down -$0.33 after Monday’s +$0.05, Friday’s +$0.40, Thursday’s -$2.94 and last Wednesday’s -$0.94 following the previous Tuesday’s -$4.13 and Monday’s +$3.24 with a positive +$0.33 or +0.70% aftermarket

Intellia Therapeutics (NTLA) closed up +0.20 after Friday’s -$1.15, Thursday’s-$0.99, Wednesday’s -$0.54, Tuesday’s -$0.85 and last Monday’s +$0.77 with a negative -$0.03 or -0.21% pre-market. NTLA unveiled promising P1 clinical trial results for Nexiguran Ziclumeran, a CRISPR-based gene-editing therapy aimed at treating transthyretin amyloidosis. The therapy demonstrated significant reduction in serum TTR levels and showed stabilization or improvement in disease markers over 12 months. The trial highlights Nexiguran’s potential as a one-time treatment option, with favorable safety and tolerability, providing hope for patients with advanced heart failure and neuropathy conditions.

Moderna (MRNA) closed up +$2.66 after Friday’s -$2.92, Thursday’s -$2.37, Wednesday’s -$1.33, Tuesday’s +$0.72 and last Monday’s -$4.08 with a positive +$0.11 or +0.28% aftermarket

Regenxbio (RGNX) closed down -$0.59 after Monday’s +$0.52, Friday’s -$1.51, Thursday’s +$1.16, and last Wednesday’s +$0.18 following the previous Tuesday’s -$1.05 and Monday’s +$0.40 with a positive +$0.22 or +2.30% aftermarket

Vericel (VCEL) closed up +$2.94 after Monday’s +$0.41 with a positive +$1.05 or +1.88% aftermarket

Voyager Therapeutics (VYGR) closed down -$0.12 after Monday’s -$0.25 with a positive +$0.28 or +5.31% aftermarket

 

Negative Indication:

Tuesday, Monday, Friday, Thursday, Wednesday, Tuesday and last Monday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

Alnylam Pharmaceuticals (ALNY) closed up +$2.00 after Monday’s -$22.35, Thursday’s -$5.56, Wednesday’s -$4.35 and last Tuesday’s -$10.87 following the previous Monday’s +$2.39 with a negative -$2.34 or -1% aftermarket

Mesoblast (MESO) closed up +$0.18 after Monday’s +$0.60, Friday’s -$1.28, Thursday’s -$0.39, and last Wednesday’s +$1.76 following the previous Tuesday’s +$0.22 after Monday’s +$0.55 with a negative -$0.32 or -2.96% aftermarket 

Sage Therapeutics (SAGE) closed up +$0.11 after Monday’s -$0.32 with a negative -$0.11 or -2.24% after news (above) re P2 DIMENSION Study of dalzanemdor (SAGE-718) does not plan further development of dalzanemdor.

 

The BOTTOM LINE: It’s time for the oversold to be recognized, one of my calling cards with words!

Even IF I am early, it’s time even IF some loss …!!

I care but, I don’t re Nvidia (NVDA) earnings as it will affect today’s market, as a guide to “our universe”

  • "It's all about the guidance.
  • How enthusiastic and how aggressive [Nvidia is] on the guidance." <Tom Essaye Sevens Report>. "It's a growth story here. We all know it. It's the future. It's the next big thing. They've got to keep us excited about it via this earnings print."
  • Investors are counting down to Nvidia's results after the bell, hoping the last of the "Magnificent Seven” can provide some fresh momentum for stocks.

Ranking the end of October:     

  • 11/19 - Tuesday closed positive with 19 incliner, 14 decliners and 2 flats
  • 11/18 – Monday closed negative with 14 incliner, 20 decliners and 1 flat
  • 11/15 – Friday: closed negative with 4 incliner, 31 decliners and 1 flat
  • 11/14 – Thursday: closed negative with 3 incliner, 31 decliners and 1 flat
  • 11/13 – Wednesday: closed negative with 8 incliner, 25 decliners and 2 flats
  • 11/12 – Tuesday: closed negative with 7 incliner, 27 decliners and 1 flat
  • 11/11 – Monday closed positive with 23 incliner, 11 decliners and 1 flat
  • 11/8 – Friday: closed negative with 15 incliner, 18 decliners and 2 flats
  • 11/7 – Thursday: closed negative with 11 incliner, 20 decliners and 4 flats
  • 11/6 – Wednesday: closed positive with 26 incliner, 7 decliners and 2 flats
  • 11/5 – Tuesday closed positive with 25 incliner, 8 decliners and 2 flats
  • 11/4 – Monday closed negative with 15 incliner, 18 decliners and 2 flats
  • 11/1 - Friday advance/decline line closed positive with 26 incliner, 7 decliners and 2 flats

 

Welcome to my world of defining the “grey’ in our universe!

  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.